

BioCentriq Acquired by GC for \$73 Million

Torreya advised BioCentriq on this transaction

Yongin, South Korea and Newark, NJ, May 17, 2022

GC Corp. (KOSPI: 005250), the holding (system) company for GC Group in South Korea with major operating companies in across healthcare sectors, has purchased 100% of the shares of BioCentriq, Inc., a US-based contract development and manufacturing organization (CDMO) that designs and develops scalable cell and gene technologies. This cross-border acquisition broadens GC companies' capabilities in scaling CDMO platforms.

Founded in 2019 as a New Jersey Innovation Institute company, BioCentriq was sold for \$73 million after a bid involving over 50 companies. The company is well-positioned in the potentially \$40 billion addressable market, end-to-end CDMO for cell and gene therapy process development and clinical manufacturing with cGMP-grade clinical manufacturing facility across locations in New Jersey. The company manufactures autologous and allogeneic cell therapies and gene therapies and specializes in viral vector production, cell and viral banking, and upstream and downstream processing.

Torreya advised BioCentriq on this transaction. This highlights Torreya's strength in advising pharmaceutical service companies. Torreya has advised clients in the bioproduction and manufacturing sectors on over 8 transactions in the past 12 months.

ABOUT BIOCENTRIQ, INC.:

For more information about BioCentriq, please see: www.biocentriq.com

ABOUT GC CORP.:

For more information about GC, please see: www.gcamerica.com

Deal Press Release

Torreya Contacts

TOM BABICH

Partner and Head of Capital Markets | New York Office

tom.babich@torreya.com | +1 212.257.5811 | [BIO](#)

TOM BIRD

Partner | New York Office

tom.bird@torreya.com | +1 212.257.5806 | [BIO](#)

TIM OPLER

Partner | New York Office

tim.opler@torreya.com | +1 212.257.5802 | [BIO](#)

GWEN MELNYK

Vice President | New York Office

gwen.melnyk@torreya.com | +1 212.257.6039 | [BIO](#)



Torreya is a global advisory firm serving the life sciences industry. Please visit torreya.com for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 15 Stratford Place, London W1C 1BE. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.